{"filings":[{"id":92297,"accession_number":"0001493152-26-017833","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lixte Biotechnology cancels 500,000 options, awards equal RSUs vesting immediately to CEO, CFO, and directors","event_type":"other_material","confidence":"high","bullets":["CEO Geordan Pursglove: 350,000 options cancelled, 350,000 RSUs awarded; CFO Peter Stazzone: 50,000 each.","Directors Holloway, Primus, Felix, Sawyer: each 25,000 options cancelled and RSUs awarded.","RSUs granted under 2020 Stock Incentive Plan and vested immediately on April 15, 2026.","Committee states swap provides better retention/incentive for officers and directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103051,"accession_number":"0001493152-26-011829","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lixte Biotechnology raises CEO base salary to $360,000 effective Jan 1, 2026","event_type":"other_material","confidence":"high","bullets":["CEO Geordan Pursglove's annual base salary increased from $240,000 to $360,000.","Increase effective retroactively to January 1, 2026; initial payment includes catch-up amount.","Amendment approved by Compensation Committee and Board of Directors on March 18, 2026.","Employee may elect to receive salary in cash or restricted shares based on closing price.","Amendment filed as Exhibit 10.1 to Form 8-K dated March 18, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103050,"accession_number":"0001493152-26-009526","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lixte restructures Liora acquisition; issues 700k shares, $440k cash, Bitcoin/Ethereum for 80% stake","event_type":"m_and_a","confidence":"high","bullets":["Amended Share Exchange consolidates prior transactions; Lixte acquires 800 of 1,000 Liora shares (80%).","Consideration includes 700,000 common shares, $440,000 cash, 10.56 Bitcoin and 300 Ethereum to Orbit Capital.","Liora holds assets for LIGHT proton-based radiotherapy system acquired from Advanced Oncotherapy PLC.","Orbit retains 20% of Liora after terminating original royalty agreement and Series C Preferred exchange.","Agreement effective November 21, 2025, executed March 6, 2026 to unify multiple transaction documents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103049,"accession_number":"0001493152-26-007268","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"LIXTE appoints Sidney Braun CEO of Liora; GBP 50K signing bonus, GBP 25K monthly retainer","event_type":"leadership","confidence":"high","bullets":["Braun becomes CEO of Liora Technologies Europe Ltd., effective Feb 13, 2026.","Signing bonus of GBP 50,000 plus monthly retainer of GBP 25,000 (both excl. VAT).","If Liora is sold, Braun gets 20% of net purchase price via Allocation Deed.","Braun helped create Liora and facilitated LIXTE's acquisition of Liora's assets in Nov 2025.","He brings 20+ years healthcare experience; previously built Remicade infusion network."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119281,"accession_number":"0001493152-25-029778","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Lixte exchanges 2,700 Series C preferred for 700K common shares and 20% of Liora subsidiary","event_type":"other_material","confidence":"high","bullets":["Orbit Capital Inc. exchanged 2,700 Series C Preferred shares for 700,000 Lixte common shares and 200 ordinary shares of Liora (20% of Liora).","Upon closing, all Series C Preferred shares were cancelled and no longer outstanding.","Lixte retained 800 ordinary shares of Liora after the exchange.","Transaction was exempt from registration under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119280,"accession_number":"0001493152-25-028999","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Lixte expands ovarian cancer trial to 42 patients; expects initial data in H1 2026","event_type":"other_material","confidence":"high","bullets":["Amendment No.2 to collaborative study doubles enrollment from 21 to 42 patients for LB-100 + dostarlimab trial in ovarian clear cell carcinoma.","Lixte enters new Collaborative Research Agreement with MD Anderson; pays milestone payments up to $1.5M ($500k per event) plus 3.75% royalty on net profit.","GSK and Lixte provide drugs at no cost to institution for expanded 42-patient study; no additional GSK payments beyond original 21 subjects.","Initial data from first 21 patients expected in first half of 2026; trial led by MD Anderson includes Northwestern as second site."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119279,"accession_number":"0001493152-25-028850","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"Lixte Biotechnology raises $4.3M in registered direct offering; terminates royalty agreement","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.3M from 1,051,342 Common Units at $4.09/unit; each unit includes one share (or Pre-Funded Warrant) and one Common Warrant (exercise $3.96, 60-month term).","Offering priced at market under Nasdaq rules; expected close Dec 19, 2025.","Terminated Royalty Agreement with Orbit Capital Inc. (dated Nov 24, 2025); both parties released from claims.","Net proceeds to be used for general corporate purposes and working capital.","Spartan Capital Securities acted as sole placement agent with 6% fee and $85K legal expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119278,"accession_number":"0001493152-25-027219","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Lixte shareholders elect all five directors, ratify auditor, approve stock plan increase","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected: Geordan Pursglove, Jason Sawyer, Dr. Michael Holloway, Lourdes Felix, Guy Primus.","Ratification of Weinberg & Company as auditor approved with 3,080,890 for, 36,370 against, 79 abstain.","Stock plan amendment to increase shares from 2.75M to 3.5M approved with 1,984,980 for, 74,134 against, 1,500 abstain.","Broker non-votes of ~1.06M on director elections and plan amendment.","Meeting had 3,117,339 shares present out of 5,635,467 shares entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119277,"accession_number":"0001493152-25-024996","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.01","2.01","3.02","5.03","7.01","9.01"],"status":"ready","headline":"LIXTE acquires Liora Technologies' proton therapy platform; consideration includes stock, crypto, cash, royalty","event_type":"m_and_a","confidence":"high","bullets":["Consideration: 2,700 Series C Preferred shares (convertible to 2.7M common), 10.56 BTC + 300 ETH, $440K cash, and 10% royalty on net revenue up to $45M.","Liora's LiGHT proton therapy system installed at Daresbury Laboratory in UK; $300M+ invested to date.","Acquisition closed Nov 24, 2025; Liora becomes wholly owned subsidiary of LIXTE.","Series C Preferred is non-voting, convertible subject to 19.99% limit until shareholder approval at 2026 annual meeting.","CEO says LiGHT platform complements LB-100 pipeline and enables potential recurring revenue model."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135861,"accession_number":"0001641172-25-027109","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LIXTE makes $2.6M initial cryptocurrency purchase to diversify treasury","event_type":"other_material","confidence":"high","bullets":["Purchased 10.5 Bitcoin and 300 Ethereum for total of $2.6 million.","Board approved increased allocation of up to 50% of treasury to cryptocurrencies.","Cryptocurrency now represents approximately 43.6% of LIXTE's treasury holdings.","Strategy aims to strengthen treasury position and enable transactions across digital mediums."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135860,"accession_number":"0001641172-25-026448","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Lixte appoints new CFO, two board members; relocates HQ to Boca Raton","event_type":"leadership","confidence":"high","bullets":["Rene Bernards, Regina Brown, Bas van der Baan resigned from Board; CFO Robert Weingarten resigned; all departures amicable.","Peter Stazzone named CFO ($150k annual salary + options for 50k shares); Geordan Pursglove named President (already CEO/Chairman).","Lourdes Felix and Guy Primus join Board; Felix chairs Audit Committee; Primus on Audit and Compensation.","Corporate headquarters moved to Boca Raton, Florida to reduce costs and improve efficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135859,"accession_number":"0001641172-25-024680","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LIXTE raises $6.5M, adds new CEO/board members, regains Nasdaq compliance","event_type":"other_material","confidence":"high","bullets":["Completed two financings raising $6.5M gross ($5M private placement + $1.5M registered direct); proceeds for working capital.","Regained compliance for continued listing on Nasdaq Capital Market.","Geordan Pursglove appointed Chairman and CEO in June 2025; Bas van der Baan becomes President and CSO.","Nature published findings validating LB-100 mechanism; new pre-clinical study with Netherlands Cancer Institute.","Jason Sawyer and Michael Holloway joined Board as independent directors; Forman and Yen moved to Scientific Advisory Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135858,"accession_number":"0001641172-25-023628","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lixte Biotechnology updates treasury policy to allocate up to 25% to Bitcoin and other digital assets","event_type":"other_material","confidence":"high","bullets":["Board approved allocating up to 25% of corporate treasury to cryptocurrencies including Bitcoin.","Company will hold crypto assets with a fully regulated and compliant custodian.","CEO Geordan Pursglove cites long-term potential to hedge treasury and deliver shareholder returns.","Timing and size of purchases will depend on market conditions; policy retains flexibility.","Lixte is a clinical-stage biotech; treasury policy shift is a strategic capital allocation initiative."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135857,"accession_number":"0001641172-25-020408","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lixte appoints two new independent directors; CMO resigns effective July 31","event_type":"leadership","confidence":"high","bullets":["Board adds Jason Sawyer and Dr. Michael Holloway as independent directors, designated by Series B Preferred Stock holders.","Dr. Stephen Forman and Dr. Yun Yen resign from Board, will serve on Scientific Advisory Committee.","Mr. Sawyer named Chairman of Compensation Committee and member of Audit Committee.","Chief Medical Officer Dr. Jan Schellens resigns effective July 31, 2025; consulting agreement terminated.","Resignations not due to any disagreement with company operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135856,"accession_number":"0001641172-25-019900","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LIXTE Biotechnology regains Nasdaq equity compliance after $6.5M capital raise","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq hearings panel notice of compliance with Listing Rule 5550(b)(1) requiring min $2.5M equity.","Compliance achieved after closing $5.0M placement (July 2) and $1.5M direct offering (July 8).","Subject to Panel Monitor through July 15, 2026; further deficiency triggers immediate hearing requirement.","CEO states regaining compliance underscores financial health as clinical trials progress in ovarian, colon, sarcoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135855,"accession_number":"0001641172-25-018684","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nature publication validates LIXTE's PP2A approach in ovarian and colorectal cancers","event_type":"other_material","confidence":"high","bullets":["Nature study: OCCC patients with PPP2R1A mutations had significantly better overall survival on immunotherapy.","PPP2R1A inactivates PP2A, the target of LB100, providing scientific validation for LIXTE's ongoing clinical trials.","LIXTE is evaluating LB100 + checkpoint inhibitors in two trials: with GSK (dostarlimab) for OCCC and with Roche (atezolizumab) for colon cancer.","First clinical results from these trials expected in the second half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135854,"accession_number":"0001641172-25-018256","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Lixte Biotechnology closes $1.5M registered direct offering of common stock and pre-funded warrants","event_type":"other_material","confidence":"high","bullets":["Closed registered direct offering of 974,026 shares (or pre-funded warrants) at $1.54 per share for gross proceeds of ~$1.5M.","Offering comprised 210,675 common shares and pre-funded warrants for 763,351 shares; closed July 8, 2025.","Net proceeds to be used for general corporate purposes and working capital.","Spartan Capital Securities acted as exclusive placement agent; TroyGould PC provided legal counsel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135853,"accession_number":"0001641172-25-017653","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lixte closes $5.0M private placement of common stock, preferred and warrants","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.0M; $4.0M received at closing July 2, 2025; $1.0M due upon SEC registration effectiveness.","Offering includes 2,382,084 common shares (or pre-funded warrants), 3,573,130 Series B convertible preferred shares, and 6,355,214 common warrants exercisable at $1.00/share.","Series B preferred shares bear 8% cumulative non-compounding dividend, convertible 1:1, and grant holders two board seats.","Net proceeds to be used for general corporate purposes and working capital; Spartan Capital served as placement agent.","Post-offering, company believes stockholders' equity exceeds $2.5M and awaits Nasdaq compliance determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152838,"accession_number":"0001641172-25-015346","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Lixte appoints Geordan Pursglove as CEO, contingent on Nasdaq financing by July 3","event_type":"leadership","confidence":"high","bullets":["Geordan Pursglove appointed CEO and Chairman; Bastiaan van der Baan resigns as CEO, remains President and CSO.","Employment agreement with Pursglove has $240K annual salary, plus potential bonus and stock option grant for 350K shares.","Van der Baan's existing stock option for 250K shares fully vested; exercise period extended to one year after service ends.","Pursglove's appointment automatically terminates if Lixte fails to complete a financing enabling Nasdaq listing by July 3, 2025.","If financing condition not met, van der Baan to be reinstated as CEO and Chairman, and Pursglove's option grant cancelled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152837,"accession_number":"0001641172-25-011701","cik":1335105,"company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","ticker":"LIXT","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lixte receives conversion notice for 350,000 Series A Preferred shares into 72,917 common shares","event_type":"other","confidence":"high","bullets":["Notice received May 16, 2025 for 350,000 Series A Convertible Preferred shares.","Issued to an investor in 2015 and 2016; converts into 72,917 shares of common stock.","Conversion dilutes existing common equity by approximately 72,917 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}